Leadership
Meet our team
Meet our team
Management Team

Management Team

Meenu Chhabra

President & CEO

Ms. Chhabra has served as our President and CEO and a member of our Board of Directors since May 2014. Ms. Chhabra was formerly President and CEO at Allozyne. Prior to her roles as CEO, she served as VP of Business Development and Licensing at the Novartis Pharmaceuticals division of Novartis. She has also served as Chief Business Officer at BioXell SpA, a spin-off from F. Hoffmann-LaRoche’s Milan Research Institute. Ms. Chhabra has held management positions with Fresenius Kabi, Warner-Lambert Company, and Bristol-Myers Squibb. Ms. Chhabra obtained her MBA from York University and her BS from the University of Toronto.

Marija Zecevic, Ph.D.

Chief Commercial Officer

Dr. Zecevic has served as our Chief Commercial Officer since February 2019, having also held the roles of Chief Operating Officer, Chief Business Officer, and VP of Business Development. Previously, Dr. Zecevic served as Managing Director of Zebra Ventures Srl., and as the Founder and Coordinator of the Industry Liaison Office of the Italian Cystic Fibrosis Foundation. Dr. Zecevic has also held roles as Acting Head of Business Development of Allozyne and Business Development Manager at BioXell SpA. Dr. Zecevic received a PhD in Biochemistry from the Institute of Physiology at the University of Zurich, Switzerland, and an MS in International Healthcare Management from the Bocconi School of Management in Milan, Italy.

Sheila Wilson, M.B.A.

Chief Operating Officer

Ms. Wilson has served as our Chief Operating Officer since February 2019, having also held the roles of Sr. VP of Clinical Development Operations and VP of Clinical Operations. Previously, Ms. Wilson served as VP of Global Operations at Synta Pharmaceuticals, VP of Global Clinical Operations at Vertex Pharmaceuticals, Sr. VP of Operations and Quality Assurance at ePharmaSolutions and VP of US Medical Operations at Pfizer Pharmaceuticals.

Ben Munoz, M.Sc., Ph.D.

Chief Scientific Officer

Dr. Munoz has served as our Chief Scientific Officer since March 2017, having also held the roles of EVP of Drug Discovery, Sr. VP of Drug Discovery and VP of Medicinal Chemistry. Previously, Dr. Munoz served as Director of Medicinal Chemistry at the Broad Institute, as Director of Research Laboratories at Merck’s Boston laboratories. Dr. Munoz formerly served on the Board of Directors of Karyopharm Therapeutics. Dr. Munoz received his PhD in Organic Chemistry from the University of Toronto and an MS in Chemistry from Brock University.

Geoffrey S. Gilmartin, M.D., M.M.Sc.

Chief Medical Officer

Dr. Gilmartin has served as our Chief Medical Officer since July 2019, having also held the roles of Chief Medical Affairs Officer and Chief Development Officer. Previously, Dr. Gilmartin served as Sr. Medical Lead in Global Medicines Development at AstraZeneca, and Medical Lead for Kalydeco development program at Vertex Pharmaceuticals. Dr. Gilmartin is also an attending physician in the intensive care unit at Beth Israel Deaconess Medical Center and formerly served as Director of the BIDMC Sleep Disorders Center. Dr. Gilmartin received a BA in History from Dartmouth College, an MD from Brown University School of Medicine and a Master of Medical Science in clinical research from Harvard Medical School.
Previous
Next

Our Board of Directors

Mr. Arkowitz joined our Board in March 2019. Mr. Arkowitz is the Chief Financial Officer of Flexion Therapeutics, Inc. (NASDAQ: FLXN). He has over 25 years of financial and operational leadership experience in the life sciences and biotechnology industries. Prior to joining Flexion, Mr. Arkowitz served as Chief Operating Officer and CFO at Visterra, a biotechnology company which was acquired by Otsuka Pharmaceutical Co., where he led the finance, business development, corporate planning and other functions. Previously, Mr. Arkowitz was CFO and General Manager at Mascoma Corporation, a bioconversion company which was acquired by Lallemand, Inc. Mr. Arkowitz was Executive Vice President, CFO and Chief Business Officer of AMAG Pharmaceuticals (NASDAQ: AMAG), a specialty pharmaceutical company. Prior to his tenure at AMAG, he served as CFO and Treasurer of Idenix Pharmaceuticals (acquired by Merck & Co., Inc. (NYSE: MRK). Prior to his tenure at Idenix, Mr. Arkowitz spent more than 13 years at Merck & Co., Inc. where he held roles of increasing responsibility, including Vice President and Controller of the U.S. Human Health division and Controller of the Global Research and Development division, and CFO of the Canadian subsidiary. Mr. Arkowitz serves on the board of directors and as chair of the audit committee of Spring Bank Pharmaceuticals (NASDAQ: SBPH), a public biopharmaceutical company. Mr. Arkowitz has a BA in Mathematics from Brandeis University and an MBA in Finance from Columbia University Business School. We believe that Mr. Arkowitz is qualified to serve on our Board of Directors because he brings more than 25 years of finance and operations leadership experience in the healthcare, life sciences and biotechnology industries.

Mr. Berger joined our Board of Directors in February 2016. Mr. Berger is a consultant to biotechnology industry participants, including major biopharmaceutical firms, mid-capitalization biotechnology companies, specialist asset managers and venture capital companies, providing business development, strategic advisory, financing, partnering and royalty acquisition advice. Mr. Berger is also a biotechnology industry analyst with over 25 years of experience in capital markets and financial analysis. Mr. Berger worked at Sectoral Asset Management as a co-founder of the small-cap focused NEMO Fund from January 2007 through May 2008. From May 1998 to March 2003, he served at J.P. Morgan Securities, most recently as Managing Director, Equity Research and Senior Biotechnology Analyst. Previously, Mr. Berger served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger also serves on the boards of directors of ESSA Pharma, Inc. (NASDAQ: EPIX), and Kezar Life Sciences, NASDAQ: KZR), each of which is a public biotechnology company. Mr. Berger formerly served on the boards of BELLUS Health, Inc. (OTCPK: BLUSF), Seattle Genetics, Inc. (NASDAQ: SGEN), Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH), Immune Design Corp. (NASDAQ: IMDZ), Five Prime Therapeutics, Inc. (NASDAQ: FPRX), Emisphere Technologies, Inc., BioTime, Inc., and, VaxGen, Inc., each of which were public biopharmaceutical companies during Mr. Berger’s service as a director. Mr. Berger received a B.A. in International Relations and an M.A. in International Economics both from Johns Hopkins University and an M.B.A. from the Harvard Business School. He is also a Chartered Financial Analyst. We believe that Mr. Berger’s financial background and experience as an equity analyst in the biotechnology industry combined with his experience serving on the boards of directors of multiple public companies are important to our strategic planning and financing activities and make him qualified to serve as a member of our Board of Directors.

Ms. Chhabra has been serving as our President and Chief Executive Officer and a member of our Board of Directors since May 2014. From August 2007 to May 2014, Ms. Chhabra was President and Chief Executive Officer at Allozyne, Inc., a biopharmaceutical company. From December 2006 to August 2007, she served as Vice President of Business Development and Licensing at the Novartis Pharmaceuticals division of Novartis AG (NYSE: NVS). From July 2003 to November 2006, she served as Chief Business Officer at BioXell SpA, a spin-off from F. Hoffmann-LaRoche Ltd.’s Milan Research Institute (Italy), where she led corporate development and financing activities. Ms. Chhabra has also held management positions with Fresenius Kabi AG, Warner-Lambert Company, LLC, and Bristol-Myers Squibb Company (NYSE: BMY). She obtained her M.B.A. from York University and her B.Sc. from the University of Toronto. We believe that Ms. Chhabra’s operational experience with our Company gained from serving as our President, Chief Executive Officer and member of the Board of Directors, combined with her extensive experience in the biopharmaceutical industry qualify her to serve as a member of our Board of Directors.

Dr. Chowdhury joined our Board in May 2019. Dr. Chowdhury is Senior Vice President, Chief Physician-Scientist, Respiratory Inflammation and Autoimmunity, Late Stage, Research and Development Biopharmaceuticals, AstraZeneca (NYSE:AZN). Prior to that he was Senior Vice President, Research and Development, Astra Zeneca Medimmune; Head of Respiratory Inflammation and Autoimmunity (RIA) Innovative Medicine Early Development at Medimmune. Dr. Chowdhury practiced medicine for more than a decade and has more than two decades of regulatory leadership experience. Prior to joining AstraZeneca, Dr. Chowdhury served at the United States Food and Drug Administration (FDA) where he held numerous leadership roles, including Director of the Division of Pulmonary, Allergy, and Rheumatology Products at the FDA’s Center for Drug Evaluation and Research (CDER). Dr. Chowdhury has a M.B., B.S. in Medicine from University of Dhaka, Dhaka Medical College, Bangladesh, and a Ph.D. in Immunology from Memorial University of Newfoundland, Canada. He completed his residency training in Internal Medicine at the Wayne State University School of Medicine, Detroit, Michigan, and fellowship in Allergy and Immunology at the National Institutes of Health’s, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, and is double board certified in Internal Medicine and Allergy and Immunology. We believe that Dr. Chowdhury’s extensive clinical trial and regulatory strategy expertise at the FDA and with the pharmaceutical industry make him qualified to serve as a member of the Board of Directors.

Ms. Drapkin joined our Board of Directors in February 2019. Ms. Drapkin is the Chief Financial Officer at Jounce Therapeutics, Inc. She has over two decades of financial leadership experience working with private and publicly traded biotechnology and pharmaceutical companies, establishing financial infrastructure, raising capital and leading strategic financial planning. Prior to her role at Jounce, Ms. Drapkin owned a financial consulting firm, where she served as Interim CFO for numerous early stage biotechnology companies, including Avila Therapeutics (acquired by Celgene Corp. (NASDAQ: CELG)), Blueprint Medicines (NASDAQ: BPMC), Eleven Biotherapeutics (now Sesen Bio (NASDAQ: SESN)), NinePoint Medical, and Voyager Therapeutics (NASDAQ: VYGR). Prior, Ms. Drapkin served as CFO of EPIX Pharmaceuticals for four years. For the preceding ten years, she served at Millennium Pharmaceuticals, Inc. (now a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd. (NYSE: TAK)) as Director of Finance, with leadership responsibility for financial reporting, technical accounting, internal audit and Sarbanes Oxley initial implementation and compliance. Ms. Drapkin began her career in the technology and life sciences practice at PriceWaterhouseCoopers LLP (NYSE: PWC). She earned her B.S. from Babson College and is a Certified Public Accountant. We believe that Ms. Drapkin’s financial expertise and experience in the biotechnology and pharmaceutical industry make her qualified to serve as a member of our Board of Directors.

Ms. Drapkin joined our Board of Directors in February 2019. Ms. Drapkin is the Chief Financial Officer at Jounce Therapeutics, Inc. She has over two decades of financial leadership experience working with private and publicly traded biotechnology and pharmaceutical companies, establishing financial infrastructure, raising capital and leading strategic financial planning. Prior to her role at Jounce, Ms. Drapkin owned a financial consulting firm, where she served as Interim CFO for numerous early stage biotechnology companies, including Avila Therapeutics (acquired by Celgene Corp. (NASDAQ: CELG)), Blueprint Medicines (NASDAQ: BPMC), Eleven Biotherapeutics (now Sesen Bio (NASDAQ: SESN)), NinePoint Medical, and Voyager Therapeutics (NASDAQ: VYGR). Prior, Ms. Drapkin served as CFO of EPIX Pharmaceuticals for four years. For the preceding ten years, she served at Millennium Pharmaceuticals, Inc. (now a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd. (NYSE: TAK)) as Director of Finance, with leadership responsibility for financial reporting, technical accounting, internal audit and Sarbanes Oxley initial implementation and compliance. Ms. Drapkin began her career in the technology and life sciences practice at PriceWaterhouseCoopers LLP (NYSE: PWC). She earned her B.S. from Babson College and is a Certified Public Accountant. We believe that Ms. Drapkin’s financial expertise and experience in the biotechnology and pharmaceutical industry make her qualified to serve as a member of our Board of Directors.

Dr. Kelly, a co-founder of our company, has served on our Board of Directors since December 2006, when our company was founded. Since January 2019, he has served on the board of directors and as a scientist at The Scripps Research Institute. Since September 2008, he has served as the Chairman of Molecular and Experimental Medicine and the Lita Annenberg Hazen Professor of Chemistry within the Skaggs Institute of Chemical Biology at The Scripps Research Institute in La Jolla, California. From August 2000 to December 2008, he served as Dean of Graduate Studies at The Scripps Research Institute, and from July 2000 to December 2006, he also served as Vice President of Academic Affairs. Dr. Kelly also co-founded FoldRx Pharmaceuticals, Inc. and Misfolding Diagnostics Inc. He received his Ph.D. in organic chemistry from the University of North Carolina at Chapel Hill. We believe that Dr. Kelly’s long history with our company and scientific and technical expertise make him qualified to serve as a member of our Board of Directors.

Our Clinical Advisory Board

Dr. Moss is the former Chief of Pediatric Pulmonary and Allergy Divisions, and allergy-immunology and pulmonary fellowship director. Dr. Moss also served as Director of the Cystic Fibrosis Center at Stanford, and site principal investigator for Cystic Fibrosis Therapeutics Development Network, where he was also the inaugural Chair of the Protocol Review Committee from 1991 to 2009.

Dr. Davies is the site co-PI for the European CF Society Clinical Trials Network and leads their Lung Clearance Index Core facility. She has experience in clinical trial design for both investigator-initiated and pharma-sponsored studies.

Dr. Knowles is the head of 2 multicenter studies, the first, genetic modifiers of disease phenotype (severity) in cystic fibrosis lung and liver disease, which also includes a recently formed international consortium that is conducting a whole genome scan. The second is a consortium of 8 North American sites studying rare genetic disorders of mucociliary clearance. Additionally, Dr. Knowles was the site Principal Investigator at UNC Chapel Hill, and served on the Steering Committee during the inception of the Cystic Fibrosis Therapeutic Development Network.

Dr. Patel has a background in translational and clinical research with a focus on respiratory disease. In his current role as Head of Early Clinical Development, Immunology and Inflammation at Sanofi, he leads the early development group of physicians and project leaders in the clinical development of compounds for the treatment of respiratory, dermatologic, and rheumatologic diseases. Previously, he was Senior Director and Project Leader in Respiratory, Inflammation, and Autoimmunity at Astra Zeneca, Associate Medical Director at Vertex Pharmaceuticals, where he led clinical studies for CF compounds including VX-809 and VX-661. Dr. Patel trained at the Harvard Combined Program in Pulmonary and Critical Medicine and still holds a part-time faculty position at Harvard Medical School and Beth Israel Deaconess Hospital. He continues to practice Pulmonary Medicine at Beth Israel Deaconess Hospital in Boston. Dr. Patel is board certified in Pulmonary and Critical Care Medicine. He received his undergraduate degree in Mechanical Engineering at Massachusetts Institute of Technology and received his M.D., C.M. from McGill University Faculty of Medicine.

Dr. Sermet-Gaudelus has developed and conducted several therapeutic trials for cystic fibrosis for both academic and company-initiated investigations. Her research focuses on modulation of the clinical severity of cystic fibrosis depending on fluid transfer and its therapeutic applications.

Dr. Tullis is the Director of the Toronto Adult Cystic Fibrosis Clinic at St. Michael’s Hospital, and is responsible for the care of 490 adults with CF. Dr. Tullis is the Respirology Division Head at St. Michael’s Hospital, and an Adjunct Scientist at the Keenan Research Centre of Li Ka Shing Knowledge Institute. She is also the Cystic Fibrosis Canada Chair in Adult CF Research.

As Chair of the Department of Pediatrics, Dr. Zeitlin oversees the pediatric clinical and research programs at National Jewish Health. She leads the National Jewish Health for Kids pediatrics program, which encompasses care, research, and education. Other areas of her research focus on the role of chloride channels in inherited diseases of the respiratory tract, especially cystic fibrosis. In her career, she has published more than 130 peer-reviewed research articles as well as a wide variety of reviews and other publications.Dr. Zeitlin received her medical degree and her Doctor of Philosophy in Cell Biology at Yale University. She completed her residency and fellowship at the Johns Hopkins Hospital.

Our Scientific Advisory Board

Dr. Hartl received his doctoral degree in Biochemistry from the University of Heidelberg. In 1985, he moved to the laboratory of Walter Neupert in Munich where he worked on the mechanism of protein transport into mitochondria, first as a post-doctoral fellow and then as a research group leader. In 1988, he initiated work that resulted in the demonstration of the basic role of molecular chaperones in protein folding. In 1990, he joined the faculty of Memorial Sloan-Kettering Cancer Center in New York where he investigated the mechanisms of protein folding in the bacterial and eukaryotic cytosol. He reconstituted the pathway of chaperone-assisted folding in which the Hsp70 and the GroEL chaperone systems cooperate and discovered that GroEL and its co-factor GroES provide a nano-compartment for single protein molecules to fold unimpaired by aggregation. In 1993, Dr. Hartl was promoted to full professor with tenure, and in 1994 became an Investigator of the Howard Hughes Medical Institute. In 1997, he returned to Munich to head the Department of Cellular Biochemistry at the Max Planck Institute of Biochemistry (MPIB) where he continues to study the basic mechanisms of protein folding in vivo as well as the role of the protein quality machinery in diseases of aberrant folding. Dr. Hartl has received several awards for his work on chaperone-assisted protein folding, including the Gairdner Award in 2004, the Wiley Prize in 2007, and the Rosenstiel Award and Horwitz Prize in 2008.
Dr. Finley’s research has focused on understanding how the proteasome recognizes its substrates, how it coordinates deubquitination with protein degradation, how it assembles, and how it unfolds and translocates the substrate in preparation for degradation. His research, in collaboration with Dr. Randall King, has led to the discovery of a novel target, Usp14, which inhibits proteasome activity by decoupling ubiquitin tags from proteins, as well as small molecule inhibitors of Usp14 that increase turnover of neurotoxic or damaged proteins. Dr. Finley has been a Professor of Cell Biology at Harvard Medical School since 1988. He graduated from Harvard University in 1980 and received his Ph.D. from Massachusetts Institute of Technology in 1984.
Jeffery W. Kelly received his Ph.D. in organic chemistry from the University of North Carolina at Chapel Hill and performed post-doctoral research at The Rockefeller University in the area of chemistry and biology. His research focuses on the chemistry and biology of protein folding, function, and maintenance and he continues to develop novel therapeutic strategies for diseases associated with compromised proteostasis. He co-founded FoldRx Pharmaceuticals along with Dr. Susan Lindquist.
Dr. King’s research, which integrates chemical and biological approaches to the study of cell division, has focused on ubiquitin-dependent protein breakdown during mitosis. He was named Associate Professor of Cell Biology at Harvard Medical School in 2006, after serving as Assistant Professor of Cell Biology since 2000. Previously, he spent 3 years as the first Institute Fellow of the Institute of Chemistry of Cell Biology at Harvard. He received his undergraduate degree in Chemistry from Carleton College in 1988, followed by a Ph.D. in Biochemistry from UCSF in 1995 and an M.D. from Harvard Medical School in 1997.
Richard I. Morimoto holds a B.S. from the University of Illinois at Chicago, received a Ph.D. in Biology from the University of Chicago, and did postdoctoral research at Harvard University. His research on the regulation of the heat shock stress response and the function of molecular chaperones addresses questions on the integration of organismal stress in response to physiologic and environmental stress and the chronic expression of misfolded and damaged proteins. Company Management Team Board of Directors Scientific Advisory Board Clinical Advisory Board Collaborations

Want to join us?